All News
New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes
ACR Press Release
New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases.
Read Article
ACR Convergence 2025 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases
ACR Press Release
At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.
Read Article
HOPE for Pts w #fibromyalgia #FM
#Transcutaneous #electrical #nerve #stimulation + #physio
Is
Better than #PT alone
#Pragmatic #cluster #randomized #trial
Answered impt question
Does #TENS help Pts w #fibro
Too ba noTENS sham
Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
Janet Pope Janetbirdope ( View Tweet)
A randomized trial of app-based behavioral (acceptance and commitment) therapy (ACT) showed reduced pain interference and affective distress in axial SpA compared to standard of care. Acceptance was moderate, but impact was meaningful. Abstract 1461 @RheumNow #ACR25 https://t.co/sF5Ldtc61R
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#1077 More health literacy work from our group!
995 people with inflammatory arthritis: lower health literacy linked to higher absenteeism & presenteeism
Those with highest HLQ scores were mostly retired with better engagement in care
@RheumNow #ACR25
Come check out our poster! https://t.co/CaqzkjMWYB
Mrinalini Dey DrMiniDey ( View Tweet)
This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs
After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs
Interesting data, More research reqd
#ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O
Links:
sheila RHEUMarampa ( View Tweet)
#0851
Urinary Tenascin C predicts kidney function loss in lupus nephritis
170 AMP-LN patients: Tenascin C (from renal myofibroblasts) was the top predictor of eGFR decline (HR 4.6)
Proteomic 11-marker risk score (AUC 0.91) outperformed proteinuria for prognosis #ACR25 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Time for the 2nd plenary session! 🎤
#0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients.
Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP
Mrinalini Dey DrMiniDey ( View Tweet)
This morning in the plenary, same theme, but in PsA:
Similar metabolic/CV concerns
Similarly benefit from GLP-1 RA
looking at TriNetX data again, reduced MACE
Now prospective trials in rheum disease, for both metabolic benefits & disease activity?
#ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG
David Liew drdavidliew ( View Tweet)
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
Links:
sheila RHEUMarampa ( View Tweet)
RA may age the immune system by nearly two decades.
IgG glycome profiles showed inflammatory aging even in early RA, tied to low fitness & high inflammation.
Improving muscle & fitness may help reverse this biologic clock.
@RheumNow #ACR25 Abstract #0835
Jiha Lee JihaRheum ( View Tweet)
Abstract 0842
💡 Urinary biomarkers as the next frontier for monitoring lupus nephritis activity
🔹 Proteinuria didn’t track w/ histologic activity
🔹 IL-16 & sCD163 correlated at baseline only
🔹 Urinary Tenascin C & BAFF correlated w/ activity at 1 yr
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Social media based outreach to pts for research
Out of 617,207 users engaged, 6 filled the contact form
Based on this social media (knowing also promotion costs) might not be the best strategy to recruit for clinical trials
@RheumNow #ACR25 https://t.co/qCH9WXyTD7
Aurelie Najm AurelieRheumo ( View Tweet)
💊 SGLT2i vs GLP-1 in Lupus Nephritis
TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis
📊 GLP-1 use linked to better renal & CV outcomes in LN including:
⬇️ CKD progression
⬇️ Mortality
⬇️ Acute MI
@RheumNow #ACR25 https://t.co/v4LgKFDt68
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Could a sputum test predict risk for RA conversion in at-risk patients?
98 at risk pts, Converters had higher
-BL sputum CCP levels
-BL Sputum nucleosome and cit-nucleosome levels !although not asso after adjusting for sputum anti-CCP-IgA level
In converters, correlation of https://t.co/bqmQqS1Jz5
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Where do patients find informations about their RMD?
Study of 705pts
-80% search engines via smartphone 80.3%
Different pattern within 2 yrs of diagnosis vs. later stage:
-more frequent 19% vs 8%
Most users find online content -understandable 80%
-apply it in daily life 68% https://t.co/9IMvpt2ffr
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
More biomarkers predictive of conversion to clinical RA in at-risk pts
Serum PAD4 & PAD 4 levels measured in CCP+ at-risk individuals
-PAD4 (not PAD2) increased in RA Converters vs. non converters and HC
-PAD4 levels Pre-RA = RA
Within high CCP+ at risk individuals, higher https://t.co/LU5zUzui1G
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months. Most adverse events were mild (e.g., transaminitis 14.5%) and manageable. No serious infections or MACE reported. A cost-effective alternative to bDMARDs in https://t.co/JBHfNq7kYt
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
What is #nonadherence in #SLE associated with?
115 Pts w #lupus in Spain
Overall medication adherence 58%!
👇Reduced if
Male
Low education
No partner -NS adjusted analysis
Unemployed
Comorbidities
3 or more drugs/pills -NS adjusted
#ACR25 @RheumNow @ACRheum
#abst0216 https://t.co/CkG6gpiCw3
Janet Pope Janetbirdope ( View Tweet)
